Immune globulin (human) is under clinical development by Takeda Pharmaceutical and currently in Phase I for Peripheral Neuropathy (Sensory Neuropathy). According to GlobalData, Phase I drugs for Peripheral Neuropathy (Sensory Neuropathy) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Immune globulin (human)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Immune globulin (human) overview

Human Immunoglobulin (Gammabulin, Gammagard, Gammagard S/D, Kiovig, Subcuvia, Hyqvia, Iveegam) contains broad spectrum of antibodies against infectious agents. It is formulated as solution and lyophilized powder solution for intravenous, intravascular, intramuscular and subcutaneous route of administration. It is indicated as antibody replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, kwasaki disease, idiopathic thrombocytopenia purpura, primary immunodeficiency disorders, multifocal motor neuropathy, guillain barr syndrome and severe combined immunodeficiencies, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukemia (CLL), hypogammaglobulinaemia and recurrent bacterial infections in patients with multiple myeloma (MM) and hypogammaglobulinemia in patients before and after allogeneic hematopoietic stem cell transplantation (HSCT), and indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older.

It is under development for the treatment of autoimmune small fiber neuropathy, X-linked agammaglobulinemia, hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP). The drug candidate was also under development for Alzheimer's disease, myocarditis, juvenile rheumatoid arthritis, polymyositis, dermatomyositis and spinocerebellar ataxia (SCA).

Takeda Pharmaceutical overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

For a complete picture of Immune globulin (human)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.